Werbung
Werbung

PRCT

PRCT logo

PROCEPT BioRobotics Corporation Common Stock

32.83
USD
Gesponsert
-1.65
-4.80%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

32.74

-0.09
-0.26%

PRCT Ergebnisberichte

Positives Überraschungsverhältnis

PRCT übertreffen die 10 der letzten 17Schätzungen.

59%

Nächster Bericht

Datum des nächsten Berichts
23. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$96.02M
/
-$0.33
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+15.23%
/
-13.16%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+40.72%
/
-5.71%

PROCEPT BioRobotics Corporation Common Stock earnings per share and revenue

On 04. Nov. 2025, PRCT reported earnings of -0.38 USD per share (EPS) for Q3 25, beating the estimate of -0.41 USD, resulting in a 9.48% surprise. Revenue reached 83.33 million, compared to an expected 82.56 million, with a 0.93% difference. The market reacted with a -9.74% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.33 USD, with revenue projected to reach 96.02 million USD, implying an decrease of -13.16% EPS, and increase of 15.23% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
For Q3 2025, PROCEPT BioRobotics Corporation Common Stock reported EPS of -$0.38, beating estimates by 9.48%, and revenue of $83.33M, 0.93% above expectations.
The stock price moved down -9.74%, changed from $35.02 before the earnings release to $31.61 the day after.
The next earning report is scheduled for 23. Feb. 2026.
Based on 16 analysts, PROCEPT BioRobotics Corporation Common Stock is expected to report EPS of -$0.33 and revenue of $96.02M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung